Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has been given an average recommendation of “Buy” by the eight analysts that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $12.13.
STRO has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a research report on Friday, October 11th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a report on Monday, September 16th. Truist Financial dropped their target price on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 16th. Finally, Piper Sandler restated an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a research note on Friday, October 11th.
Get Our Latest Research Report on Sutro Biopharma
Institutional Investors Weigh In On Sutro Biopharma
Sutro Biopharma Price Performance
STRO opened at $3.83 on Wednesday. The business has a 50 day moving average of $3.97 and a 200-day moving average of $3.90. Sutro Biopharma has a 12-month low of $2.01 and a 12-month high of $6.13. The stock has a market cap of $313.27 million, a price-to-earnings ratio of -2.04 and a beta of 1.17.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.20. The business had revenue of $25.71 million during the quarter, compared to the consensus estimate of $26.28 million. Sutro Biopharma had a negative net margin of 73.48% and a negative return on equity of 102.06%. As a group, analysts expect that Sutro Biopharma will post -2.96 earnings per share for the current year.
About Sutro Biopharma
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Read More
- Five stocks we like better than Sutro Biopharma
- Options Trading – Understanding Strike Price
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Insider Buying Explained: What Investors Need to Know
- AMD Gains Momentum With AI: Can It Beat Expectations?
- How to Choose Top Rated Stocks
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.